Press Release: Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
BY Dow Jones & Company, Inc.— 7:29 AM ET 08/04/2020
Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
Company reports second quarter 2020 XHANCE net revenue of $10.3 million
Second quarter 2020 XHANCE prescriptions increased 84% from second quarter 2019 (My emphasis- MG)
Conference call and webcast to be held today at 8:00 a.m. Eastern Time
YARDLEY, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Optinose ( OPTN ) , a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2020, and provided operational updates.
"XHANCE prescription volume continued to grow in the second quarter, which was impressive given the major disruptions to patient volumes and care pathways within ENT and allergy physician practices," stated CEO Peter Miller. "XHANCE had exceptionally strong market share growth, demonstrating remarkable resilience, as we successfully adapted our business to the COVID-19 environment. We are excited by the potential for XHANCE to continue to grow and recently announced a co- promotion with kaléo that will amplify our effort. We look forward to a strong partnership that we believe can have meaningful impact."
News 
Market Data 
Discover 
